MedTrace Logo

everlinQ endoAVF Post Market Study

NCT02682420 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-12-11

Study results available
· View outcomes & findings →

Summary

Prospective, multi-center study to evaluate the everlinQ endoAVF System when used to create an endovascular arteriovenous fistula (endoAVF) for patients who require vascular access for hemodialysis.

Conditions

Interventions

DEVICE

everlinQ endoAVF System

Sponsors & Collaborators

  • C. R. Bard

    lead INDUSTRY

Principal Investigators

  • Nicholas Inston, MD · University Hospitals Birmingham NHS

  • Thomas Schmitz-Rixen, MD · Univerisity of Frankfurt, Germany

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-20
Primary Completion
2019-08-31
Completion
2019-08-31

Countries

  • Canada
  • Germany
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02682420 on ClinicalTrials.gov